癌症免疫治疗市场：依治疗类型、给药途径、癌症类型、通路和地区划分

2025 年全球癌症免疫治疗市场规模估计为 1,584.2 亿美元，预计到 2032 年将达到 3,570.7 亿美元，2025 年至 2032 年的复合年增长率为 12.3%。

数字。 2025 年各地区癌症免疫治疗市场占有率（%）

癌症免疫疗法是一种利用人体免疫系统对抗癌症的癌症治疗方法。这是一种创新方法，利用免疫系统的力量并对其进行修改以增强人体对抗癌症的天然防御能力。癌症免疫疗法包括单株抗体、查核点抑制剂、白细胞介素抑制剂和治疗性癌症疫苗等治疗方法。最近的科学进展使人们对癌细胞和免疫系统之间的复杂相互作用有了更深入的了解，从而引起了人们越来越浓厚的兴趣。癌症免疫疗法是一种新的治疗模式，有可能在未来大幅改变癌症治疗方法。

市场动态：

全球癌症免疫治疗市场的成长受到多种因素的推动，例如全球癌症发病率不断上升、对有效标靶治疗的需求不断增加，以及与传统治疗方法相比，癌症免疫治疗具有更高的治疗成功率。癌症仍然是死亡的主要原因之一，预计在不久的将来全球癌症负担将大幅增加。这是免疫疗法被采用的主要动力。生物技术的进步和我们对癌症免疫学的理解为开发新型免疫疗法和改善患者治疗效果铺平了道路。然而，免疫疗法药物的高成本、对专门基础设施和医疗保健人力的需求以及与免疫疗法相关的安全问题是限制市场成长的一些挑战。该领域的积极研究和开发、针对新癌症类型的研发以及正在进行的临床试验有可能为市场参与者提供成长机会。

本研究的主要特点

• 本报告对全球癌症免疫治疗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 该报告根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球免疫肿瘤学市场的主要企业。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球癌症免疫疗法市场报告涵盖该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球免疫肿瘤学市场的各种策略矩阵来促进他们的决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 市场机会
• 影响分析
• 市场趋势
• 最新动态
• 收购和合作场景
• 技术概述
• 监管情景
• 定价分析
• PEST分析

第 4 章全球癌症免疫治疗市场-冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020 年至 2032 年全球癌症免疫疗法市场（按治疗类型划分）（十亿美元）

• 免疫查核点抑制剂
• 疫苗
• 预防疫苗
• 治疗性疫苗
• 过继细胞治疗
• 肿瘤浸润淋巴细胞 (TIL) 治疗
• CAR-T 细胞疗法
• 工程 T 细胞受体 (TCR) 疗法
• 自然杀手（NK）细胞疗法
• 免疫系统调节剂
• 干扰素
• 免疫调节药物 (IMiD)
• 白细胞介素
• 单株抗体
• 裸露的单株抗体
• 结合单株抗体
• 双特异性单株抗体
• 溶瘤病毒治疗

6. 2020 年至 2032 年按给药途径分類的全球癌症免疫治疗市场（十亿美元）

• 皮下
• 口服
• 肌肉注射
• 静脉注射 (IV)
• 其他的

7. 2020 年至 2032 年全球癌症免疫治疗市场（按癌症类型划分）（十亿美元）

• 淋巴瘤
• 乳癌
• 大肠直肠癌
• 膀胱癌
• 皮肤癌
• 肺癌
• 肾癌
• 其他的

8. 2020 年至 2032 年全球癌症免疫治疗市场按通路划分（十亿美元）

• 医院药房
• 零售药局
• 网路药局

9. 2020 年至 2032 年全球癌症免疫治疗市场（按地区划分）（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区

Global Cancer Immunotherapy Market is estimated to be valued at USD 158.42 Bn in 2025 and is expected to reach USD 357.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Figure. Cancer Immunotherapy Market Share (%), By Region 2025

Cancer immunotherapy is a type of cancer treatment that utilizes the body's own immune system to fight against cancer. It is an innovative approach that harnesses the power of the immune system and modifies it to enhance the body's natural defenses against cancer. Cancer immunotherapy comprises therapies like monoclonal antibodies, checkpoint inhibitors, interleukin inhibitors, therapeutic cancer vaccines and others. It is gaining prominence as recent scientific breakthroughs have improved understanding of the complex interaction between tumor cells and the immune system. Cancer immunotherapy represents a novel treatment paradigm that has the potential to transform the way cancer is treated in the future.

Market Dynamics:

Global cancer immunotherapy market growth is driven by factors such as increasing prevalence of cancer worldwide, rising demand for effective targeted therapies, and higher treatment success rates associated with cancer immunotherapy as compared to conventional treatment modalities. Cancer remains one of the leading causes of mortality and the global burden of cancer is expected to rise significantly in the near future. This is providing a major boost to immunotherapy adoption. Advancements in biotechnology along with better understanding of cancer immunology have led to the development of novel immunotherapies, which are paving the way for improved patient outcomes. However, high costs associated with immunotherapy drugs, need for specialized infrastructure and healthcare personnel, and safety concerns related to immunotherapy are some of the challenges restraining the market growth. Active R&D in this field, targeting new cancer types, and ongoing clinical trials hold potential to provide growth opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global cancer immunotherapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, and Incyte.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cancer immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer immunotherapy market.

Detailed Segmentation-

• Therapy Type:
  • Immune checkpoint inhibitors
  • Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
  • Adoptive Cell Therapies
  • Tumor-infiltrating lymphocyte (TIL) therapy
  • CAR T-cell therapy
  • Engineered T-cell receptor (TCR) therapy
  • Natural killer (NK) cell therapy
  • Immune System Modulators
  • Interferons
  • Immunomodulators (IMiDs)
  • Interleukins
  • Monoclonal antibodies
  • Naked monoclonal antibodies
  • Conjugated monoclonal antibodies
  • Bispecific monoclonal antibodies
  • Oncolytic Virus Therapy
• Route of Administration:
  • Subcutaneous
  • Oral
  • Intramuscular
  • Intravenous (IV)
  • Others
• Cancer Type:
  • Lymphoma
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Skin Cancer
  • Lung Cancer
  • Kidney Cancer
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Cancer Immunotherapy Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Cancer Immunotherapy Market, By Therapy Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Immune checkpoint inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Preventive Vaccines
• Therapeutic Vaccines
• Adoptive Cell Therapies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tumor-infiltrating lymphocyte (TIL) therapy
• CAR T-cell therapy
• Engineered T-cell receptor (TCR) therapy
• Natural killer (NK) cell therapy
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Interferons
• Immunomodulators (IMiDs)
• Interleukins
• Monoclonal antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Oncolytic Virus Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cancer Immunotherapy Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intramuscular
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous (IV)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cancer Immunotherapy Market, By Cancer Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Skin Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Kidney Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cancer Immunotherapy Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Cancer Immunotherapy Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Gilead Sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact